文献速递骨软组织肉瘤与黑色素瘤

套细胞淋巴瘤患者的第二原发恶性肿瘤

Secondary malignancies among mantle cell lymphoma patients.
PubMed 文献 · Eur J Cancer · 2023-10-29

在瑞典开展的一项基于人群的队列研究纳入2000–2017年确诊的1452例套细胞淋巴瘤(MCL)患者及13992例匹配对照,随访平均6.6年,患者发生第二原发恶性肿瘤(SM)的风险高于对照(HRadj=1.6,95%CI 1.4–1.8);与Nordic-MCL2方案相比,R-苯达莫司汀治疗与SM风险升高独立相关(HRadj=2.0,95%CI 1.3–3.2)。

要点

  • MCL患者SM发生率高于匹配对照,HRadj=1.6(95%CI 1.4–1.8)。
  • 与Nordic-MCL2方案相比,R-苯达莫司汀治疗与SM风险升高独立相关,HRadj=2.0(95%CI 1.3–3.2)。
  • 患者中SM风险较高的亚组为诊断时年龄较高(p < 0.001)、男性(p = 0.006)和有淋巴瘤家族史(p = 0.009)。

核心结论

  • MCL幸存者发生SM的风险升高,尤其是接受R-苯达莫司汀治疗者。
  • 作者认为,为获得长期缓解所需的强化治疗令人担忧,需要转向持续有效但SM风险更低的治疗方案。

研究设计与样本

  • 基于瑞典人群的研究,纳入2000–2017年确诊、年龄≥18岁的MCL患者,并按1:10匹配一般人群对照。
  • 共纳入1452例患者和13992例对照,随访从诊断或匹配后12个月起至死亡、移居或2019年12月(以先发生者为准)。
  • 采用Anderson-Gill方法估计SM发生率(考虑重复事件),以危险比(HR)及95%置信区间(CI)表示,并校正诊断时年龄、日历年、性别和既往事件数。

主要发现

  • 患者平均随访6.6年;230例(16%)患者发生至少一种SM,共观察到264例SM。
  • 与对照相比,患者SM发生率更高,HRadj=1.6(95%CI 1.4–1.8)。
  • 在所有主要治疗组(Nordic-MCL2方案、R-CHOP、R-苯达莫司汀、伊布替尼、来那度胺、R-CHOP/阿糖胞苷)中均观察到SM发生率升高。
  • 与Nordic-MCL2方案相比,R-苯达莫司汀治疗与SM风险升高独立相关,HRadj=2.0(95%CI 1.3–3.2)。
  • 患者中SM风险较高的因素为诊断时年龄较高(p < 0.001)、男性(p = 0.006)和有淋巴瘤家族史(p = 0.009),且患者黑色素瘤、其他皮肤肿瘤及其他造血和淋巴系统恶性肿瘤风险更高。

临床怎么用

  • 作者认为,MCL幸存者SM风险升高,尤其在接受R-苯达莫司汀治疗者中,需要转向持续有效但SM风险更低的治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: With modern treatments, mantle cell lymphoma (MCL) patients more frequently experience long-lasting remission resulting in a growing population of long-term survivors. Follow-up care includes identification and management of treatment-related late-effects, such as secondary malignancies (SM). We conducted a population-based study to describe the burden of SM in MCL patients. METHODS: All patients with a primary diagnosis of MCL, aged ≥ 18 years and diagnosed between 2000 and 2017 in Sweden were included along with up to 10 individually matched population comparators. Follow-up was from twelve months after diagnosis/matching until death, emigration, or December 2019, whichever occurred first. Rates of SM among patients and comparators were estimated using the Anderson-Gill method (accounting for repeated events) and presented as hazard ratios (HR) with 95% confidence intervals (CI) adjusted for age at diagnosis, calendar year, sex, and the number of previous events. RESULTS: Overall, 1 452 patients and 13 992 comparators were followed for 6.6 years on average. Among patients, 230 (16%) developed at least one SM, and 264 SM were observed. Relative to comparators, patients had a higher rate of SM, HRadj= 1.6 (95%CI:1.4-1.8), and higher rates were observed across all primary treatment groups: the Nordic-MCL2 protocol, R-CHOP, R-bendamustine, ibrutinib, lenalidomide, and R-CHOP/Cytarabine. Compared to Nordic-MCL2, treatment with R-bendamustine was independently associated with an increased risk of SM, HRadj= 2.0 (95%CI:1.3-3.2). Risk groups among patients were those with a higher age at diagnosis (p < 0.001), males (p = 0.006), and having a family history of lymphoma (p = 0.009). Patients had preferably higher risk of melanoma, other neoplasms of the skin and other hematopoietic and lymphoid malignancies. CONCLUSIONS: MCL survivors have an increased risk of SM, particularly if treated with R-bendamustine. The intensive treatments needed for long-term remissions are a concern, and transition to treatment protocols with sustained efficacy but with a lower risk of SM is needed.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Abalo KD, Smedby KE, Ekberg S, et al. Secondary malignancies among mantle cell lymphoma patients. Eur J Cancer. 2023. PMID: 37952281. doi:10.1016/j.ejca.2023.113403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。